Clinical Trials Logo

Recurrent or Progressive Malignant Glioma clinical trials

View clinical trials related to Recurrent or Progressive Malignant Glioma.

Filter by:
  • None
  • Page 1

NCT ID: NCT00539344 Completed - Clinical trials for Recurrent or Progressive Malignant Glioma

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

Start date: October 2007
Phase: Phase 1
Study type: Interventional

This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with recurrent or progressive malignant glioma. ANG1005 will be given by IV infusion once every 21 days (1 treatment cycle). Each patient will participate in only 1 dose group and will receive up to 6 cycles of treatment provided there is no evidence of tumor progression, there is recovery to ≤Grade 1 or baseline nonhematologic, ANG1005-related toxicity (except alopecia), the absolute neutrophil count is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L.